Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 16, 2005. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share allocation adjustments within a retirement plan.
Material Changes
There are no material changes to the company's financial position reported in this filing. The document details increases in the notional allocation of Ordinary Share ADRs for specific individuals due to fund movements on August 4 and August 12, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- The filing reports notional increases in GSK Ordinary Share ADRs held within the US Retirement Savings Plan for nine named directors and executives.
- Share price movements triggering these allocations were recorded at $47.93 per ADR on August 4, 2005, and $47.88 per ADR on August 12, 2005.
- Mr. D Phelan received the largest notional allocation increase (143 shares) among the listed individuals.
- This document does not contain financial performance data or strategic updates for the company.